Natcofarma DO Brasil Ltda Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: Natcofarma DO Brasil Ltda Pharmaceutical Import Records from India — 3 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Natcofarma DO Brasil Ltda — Pharmaceutical Importer Profile (2026) | 3 Products, $1.4M Trade | TransData Nexus

Natcofarma DO Brasil Ltda

Pharmaceutical Importer · Brazil · Cardiovascular Focus · $1.4M Total Trade · DGFT Verified

Natcofarma DO Brasil Ltda is a pharmaceutical importer based in Brazil with a total trade value of $1.4M across 3 products in 3 therapeutic categories. Based on 27 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Natcofarma DO Brasil Ltda sources from 1 verified Indian supplier, with Natco Pharma Limited accounting for 100.0% of imports.

Natcofarma DO Brasil Ltda — Import Portfolio & Supplier Network

Natcofarma DO Brasil Ltda import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Natcofarma DO Brasil Ltda?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Natco Pharma Limited	$3.3M	133	100.0%

Natcofarma DO Brasil Ltda sources from 1 verified Indian supplier across 117 distinct formulations. The sourcing is highly concentrated — Natco Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Natcofarma DO Brasil Ltda Import?

Formulation	Value	Ships
Apixaban 2.5MG tablets 60's (appendix	$150.0K	3
Everolimus 10MG tablets 28's (913x28's)(appendix 4r, rodtep entry no:10112)(other ref(s)cino:124040)	$150.0K	3
Apixaban 2.5MG tablets 20's (appendix	$132.4K	3
Azacitidine for injection 100MG (other	$100.0K	2
Apixaban 5MG tablets 60's (appendix 4r	$100.0K	2
Apixaban 5MG tablets 20's (appendix 4r	$100.0K	2
Oseltamivir phosphate 75MG capsules	$82.9K	2
Apixaban 2.5MG tablets 20?s (other	$50.0K	1
Apixaban 2.5MG tablets 60?s (other	$50.0K	1
Apixaban 5MG tablets 20?s (other	$50.0K	1
Apixaban 5MG tablets 60?s (other	$50.0K	1
Xakilis 2.5MG tablets 60's (other	$50.0K	1
Xakilis 5MG tablets 60's(other	$50.0K	1
Xakilis 2.5 MG tablets 10's(other	$50.0K	1
Everolimus 5MG tablets 28's (other	$50.0K	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Apixaban	Cardiovascular	$600.0K	12	0.3%	11
2	Everolimus	Immunosuppressants	$550.0K	11	1.5%	9
3	Gefitinib	Advanced Oncology	$200.0K	4	1.5%	3

Natcofarma DO Brasil Ltda imports 3 pharmaceutical products across 3 categories into Brazil totaling $1.4M.

Natcofarma DO Brasil Ltda — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Natcofarma do Brasil Ltda is a Brazilian pharmaceutical company specializing in the importation and distribution of finished pharmaceutical formulations. Established as a subsidiary of Natco Pharma Limited, an Indian pharmaceutical company, Natcofarma do Brasil Ltda leverages its parent company's research and development capabilities to provide affordable medications in Brazil. The company offers a variety of generic medications, particularly in therapeutic areas such as oncology, hematology, cardiology, neurology, and primary care.

The company's headquarters are located in Serra, Espírito Santo, Brazil. Natcofarma do Brasil Ltda operates as a subsidiary of Natco Pharma Limited, an Indian pharmaceutical company. The company plays a significant role in Brazil's pharmaceutical distribution network by importing and distributing finished pharmaceutical formulations, thereby enhancing the availability of affordable medications in the Brazilian market.

2Distribution Network

Natcofarma do Brasil Ltda maintains a distribution network that includes its headquarters in Serra, Espírito Santo, and a branch in São Paulo, São Paulo. The company's logistics capabilities are designed to ensure efficient importation and distribution of pharmaceutical products across Brazil. While specific warehouse locations and geographic coverage details are not publicly disclosed, the company's infrastructure supports the nationwide distribution of its products.

3Industry Role

In Brazil's pharmaceutical supply chain, Natcofarma do Brasil Ltda functions primarily as a pharmaceutical importer and distributor. The company imports finished pharmaceutical formulations from its parent company, Natco Pharma Limited, and distributes them within Brazil. This role positions Natcofarma do Brasil Ltda as a key player in enhancing the accessibility of affordable medications in the Brazilian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Natcofarma DO Brasil Ltda

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Natcofarma do Brasil Ltda's sourcing strategy is highly concentrated, with all its pharmaceutical imports originating from a single supplier: Natco Pharma Limited. This single-source dependency indicates a strategic choice to maintain a consistent supply of high-quality products from a trusted partner. The shipment data reveals a stable and ongoing relationship, as evidenced by 27 shipments totaling $1.4 million USD over the period from 2022 to 2026. This consistent sourcing pattern suggests a reliable and enduring partnership between Natcofarma do Brasil Ltda and Natco Pharma Limited.

2Supply Chain Resilience

The resilience of Natcofarma do Brasil Ltda's supply chain is closely tied to its exclusive reliance on Natco Pharma Limited for pharmaceutical imports. While this single-source strategy ensures product consistency and quality, it also exposes the company to potential risks associated with supply chain disruptions. The lack of backup suppliers and limited formulation diversity may pose challenges in the event of production issues or regulatory changes affecting the primary supplier. Additionally, the company's exposure to shipping routes and potential regulatory compliance issues is concentrated, which could impact supply chain stability.

Strategic Implications

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the primary regulatory authority overseeing pharmaceutical products is the Agência Nacional de Vigilância Sanitária (ANVISA). ANVISA is responsible for the regulation and supervision of health-related products and services, including the authorization of clinical trials, active pharmaceutical ingredients (APIs), and marketing authorization of drugs and biological products. (gov.br)

Key legislation governing pharmaceutical imports into Brazil includes Law 9.782/1999, which established the National Health Surveillance System, and Law 9.879/1999, which created ANVISA. These laws provide the legal framework for the regulation of health-related products and services in Brazil. (gov.br)

The marketing authorization pathway for Indian generics involves obtaining approval from ANVISA, which includes demonstrating compliance with Brazilian sanitary regulations. This process ensures that imported pharmaceutical products meet the required quality and safety standards before being marketed in Brazil. (gov.br)

2Import Licensing & GMP

Import licensing requirements in Brazil are managed by ANVISA, which oversees the authorization of pharmaceutical imports to ensure compliance with national health regulations. Importers must obtain the necessary licenses and approvals before distributing pharmaceutical products within Brazil. (gov.br)

Natcofarma DO Brasil Ltda — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Natcofarma do Brasil Ltda's product strategy focuses on importing and distributing generic medications in therapeutic areas such as oncology, hematology, cardiology, neurology, and primary care. This focus aligns with the company's mission to provide affordable and high-quality medications to the Brazilian market. The demand for these therapeutic areas is driven by the prevalence of related health conditions in Brazil and the need for accessible treatment options.

2Sourcing Profile

Natcofarma do Brasil Ltda's sourcing strategy is centered on importing finished pharmaceutical formulations from its parent company, Natco Pharma Limited. This approach ensures a consistent supply of high-quality generic medications that meet international standards. The company's focus on sourcing from a single supplier reflects a strategic decision to maintain product consistency and reliability.

3Market Positioning

Based on its product mix, Natcofarma do Brasil Ltda serves the Brazilian pharmaceutical market by importing and distributing generic medications to various segments, including retail pharmacies, hospitals, and government tenders. The company's focus on affordability and quality positions it as a key player in enhancing the accessibility of essential medications across Brazil.

Seller's Guide — How to Become a Supplier to Natcofarma DO Brasil Ltda

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Natcofarma do Brasil Ltda, given the company's exclusive reliance on Natco Pharma Limited for its pharmaceutical imports. Potential gaps in Natcofarma do Brasil Ltda's current sourcing include the need for additional suppliers to mitigate supply chain risks and diversify product offerings. Indian exporters can explore these opportunities by ensuring compliance with Brazilian regulatory requirements and offering products that align with Natcofarma do Brasil Ltda's quality standards.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Natcofarma do Brasil Ltda and the Brazilian market must obtain the necessary import licenses from ANVISA and ensure compliance with recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S. Additionally, products must meet Brazilian labeling requirements, including the use of the Portuguese language and adherence to specific formatting and content guidelines. Compliance with these standards is essential for successful market entry. (gov.br)

3How to Approach

Frequently Asked Questions — Natcofarma DO Brasil Ltda

What products does Natcofarma DO Brasil Ltda import from India?

Natcofarma DO Brasil Ltda imports 3 pharmaceutical products across 3 categories. Top imports: Apixaban ($600.0K), Everolimus ($550.0K), Gefitinib ($200.0K).

Who supplies pharmaceuticals to Natcofarma DO Brasil Ltda from India?

Natcofarma DO Brasil Ltda sources from 1 verified Indian suppliers. The primary supplier is Natco Pharma Limited (100.0% of imports, $3.3M).

What is Natcofarma DO Brasil Ltda's total pharmaceutical import value?

Natcofarma DO Brasil Ltda's total pharmaceutical import value from India is $1.4M, based on 27 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Natcofarma DO Brasil Ltda focus on?

Natcofarma DO Brasil Ltda imports across 3 categories. The largest: Cardiovascular (44.4%), Immunosuppressants (40.7%), Advanced Oncology (14.8%).

Get Full Natcofarma DO Brasil Ltda Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.